These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2573989)

  • 21. Thyroid function and immunological activity during and after medical treatment of Graves' disease.
    Gossage AA; Crawley JC; Copping S; Hinge D; Himsworth RL
    Clin Endocrinol (Oxf); 1983 Jul; 19(1):87-96. PubMed ID: 6137296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medical therapy of Graves' disease: does thyroxine prevent recurrence of hyperthyroidism?
    Lucas A; Salinas I; Rius F; Pizarro E; Granada ML; Foz M; Sanmartí A
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2410-3. PubMed ID: 9253309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of thyroid stimulating antibodies and TSH-binding inhibiting immunoglobulins in the follow-up of Graves' disease.
    Hörmann R; Saller B; Müller R; Mann K
    Klin Wochenschr; 1985 Dec; 63(24):1247-52. PubMed ID: 2868149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs.
    Michelangeli V; Poon C; Taft J; Newnham H; Topliss D; Colman P
    Thyroid; 1998 Feb; 8(2):119-24. PubMed ID: 9510119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
    Ochi Y; Kajita Y; Hamazu M; Nagata A
    Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid function parameters and TSH-receptor antibodies in healthy subjects and Graves' disease patients: a sequential study before, during and after pregnancy.
    González-Jiménez A; Fernández-Soto ML; Escobar-Jiménez F; Glinoer D; Navarrete L
    Thyroidology; 1993 Apr; 5(1):13-20. PubMed ID: 7508738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-TSH antibodies in Graves' disease and their failure to interact with TSH receptor antibodies.
    Ochi Y; Nagamune T; Nakajima Y; Ishida M; Kajita Y; Hachiya T; Ogura H
    Acta Endocrinol (Copenh); 1989 Jun; 120(6):773-7. PubMed ID: 2567103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thyrotropin receptor non-mediated thyroid stimulating immunoglobulin in Graves' disease.
    Endo T; Haraguchi K; Ohmori M; Ikeda M; Ohta K; Onaya T
    Biochem Biophys Res Commun; 1991 Sep; 179(3):1543-7. PubMed ID: 1656957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence against the importance in the disease process of antibodies to bovine thyroid-stimulating hormone found in some patients with Graves' disease.
    Noh J; Hamada N; Saito H; Oyanagi H; Ishikawa N; Momotani N; Ito K; Morii H
    J Clin Endocrinol Metab; 1989 Jan; 68(1):107-13. PubMed ID: 2909548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of cells expressing the human thyrotropin (TSH) receptor for the measurement of thyroid stimulating and TSH-blocking antibodies.
    Vitti P; Chiovato L; Fiore E; Mammoli C; Rocchi R; Pinchera A
    Acta Med Austriaca; 1996; 23(1-2):52-6. PubMed ID: 8767515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
    Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
    Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The extracellular domain of the TSH receptor has an immunogenic epitope reactive with Graves' IgG but unrelated to receptor function as well as determinants having different roles for high affinity TSH binding and the activity of thyroid-stimulating autoantibodies.
    Kosugi S; Akamizu T; Takai O; Prabhakar BS; Kohn LD
    Thyroid; 1991; 1(4):321-30. PubMed ID: 1726785
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK; Yoo WS; Kim DW; Chung HK
    Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor.
    Vitti P; Elisei R; Tonacchera M; Chiovato L; Mancusi F; Rago T; Mammoli C; Ludgate M; Vassart G; Pinchera A
    J Clin Endocrinol Metab; 1993 Feb; 76(2):499-503. PubMed ID: 8094393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of Chinese hamster ovary cell lines transfected with cloned human thyrotropin receptor for the measurement of thyroid-stimulating antibodies: advantages and difficulties.
    Massart C; Gibassier J; Vérité F; Fergelot P; Maugendre D
    Clin Chim Acta; 2000 Jan; 291(1):67-81. PubMed ID: 10612718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of tsh binding inhibiting antibodies (TBI-ab) and thyroid adenylate cyclase stimulating antibodies (TS-ab) in sera of patients with Graves' disease.
    Lattanzi V; Scardapane R; Ciampolillo A; Vincenti C; Giorgino R
    Boll Soc Ital Biol Sper; 1985 Jan; 61(1):55-60. PubMed ID: 3838478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.